ABBOTT LABORATORIES | 29,015 Euro | -0,925 -3,09 % | |
| WKN: 850103 ISIN: US0028241000 Ticker-Symbol: ABL | Frankfurt | 23.05.13 | 15:46 Uhr |
Branche PharmaAktienmarkt S&P 100S&P 500 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 14:55 | Abbott Laboratories: Undervalued Potential | 3 | Seeking Alpha | |
| 22.05. | Abbott Laboratories' Management Presents at UBS Global Healthcare Conference (Transcript) | 5 | Seeking Alpha | |
| 22.05. | Abbott to Present at Deutsche Bank 38th Annual Health Care Conference | 16 | PR Newswire | |
| ABBOTT PARK, Ill., May 22, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will participate in the Deutsche Bank 38th Annual Health Care Conference on Wednesday, May 29, 2013. Thomas C. Freyman... Mehr lesen zu: Abbott to Present at Deutsche Bank 38th Annual Health Care Conference | ||||
| 21.05. | Abbott Announces CE Mark For Xience Xpedition 48 Coronary Stent System | 48 | AFX News | |
| NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) Tuesday announced CE
Mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent
System, the first-of-its-kind treatment... Mehr lesen zu: Abbott Announces CE Mark For Xience Xpedition 48 Coronary Stent System | ||||
| 21.05. | Abbott (ABT) Receives CE Mark for XIENCE Coronary Stent System | - | StreetInsider.com | |
| 21.05. | Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent | 31 | PR Newswire | |
| ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT)today announced CE Mark in Europe for the XIENCE Xpedition' 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment... Mehr lesen zu: Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent | ||||
| 21.05. | Abbott denounces Government's Brisbane rail funding pledge | 1 | ABC online | |
| 20.05. | Goldman Sachs stuft Abbott Labs von Neutral auf Buy hoch | 120 | BörseGo | |
| Goldman Sachs stuft Abbott Labs von Neutral auf Buy hoch
(© BörseGo AG 2013 - Autor: Thomas Gansneder, Redakteur) Mehr lesen zu: Goldman Sachs stuft Abbott Labs von Neutral auf Buy hoch | ||||
| 20.05. | Abbott Laboratories lifted to buy at Goldman Sachs | 4 | MarketWatch | |
| 18.05. | Abbott Laboratories Stock Checkup for May | 3 | Motley Fool | |
| 17.05. | Abbott super delay a 'bitter disappointment' | 12 | The Age | |
| 17.05. | Abbott falls $26 billion short: Gillard | 6 | Yahoo-AU | |
| 17.05. | Abbott forecasts 'fair bit' of saving | 2 | Yahoo-AU | |
| 16.05. | Abbott should tell all in budget reply: PM | 4 | Yahoo-AU | |
| 15.05. | Abbott not committing on budget measures | - | Yahoo-AU | |
| 14.05. | Abbott cagey on coalition aid plans | 1 | Yahoo-AU | |
| 11.05. | Jury orders Abbott Labs to pay $2 million in Humira suit | 8 | bizjournals | |
| 10.05. | Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million | 121 | PR Newswire | |
| CHICAGO, May 9, 2013 /PRNewswire/ -- Today, a Cook County jury entered a verdictfinding Abbott Laboratories negligent and ordering it to pay $2,244,063.20 to Plaintiff Milton Tietz on behalf of his... Mehr lesen zu: Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million | ||||
| 09.05. | Abbott Gets CE Marking For ARCHITECT Clinical Chemistry Hemoglobin A1c Test | 75 | AFX News | |
| NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) Thursday announced CE
Marking for the ARCHITECT clinical chemistry Hemoglobin A1c or HbA1c test, which
the firm said may aid physicians... Mehr lesen zu: Abbott Gets CE Marking For ARCHITECT Clinical Chemistry Hemoglobin A1c Test | ||||
| 09.05. | Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes | 61 | PR Newswire | |
| ABBOTT PARK, Illinois, May 9, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c (HbA1c) test, which may... Mehr lesen zu: Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| NOVARTIS | 57,05 | -2,35 % | Novartis hat kein Interesse an Actavis |
| PFIZER | 22,475 | -2,07 % | Pfizer spaltet Tierarzneisparte Zoetis endgültig ab |
| NOVO NORDISK | 130,90 | -1,98 % | Novo Nordisk and Paula Deen Announce Winners of the Seeing Diabetes in a New Light' Contest |
| ASTRAZENECA | 40,22 | -0,76 % | AstraZeneca's Naloxegol Meets Primary End Point In Late-stage Trial |
| SANOFI | 85,00 | -1,66 % | S&P Equity hebt Ziel für Sanofi auf 92 Euro - 'Buy' |
